Tag Archives: SYRS

Analysts Are Bullish on Top Healthcare Stocks: Syros Pharmaceuticals (SYRS), Argenx Se (ARGX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Syros Pharmaceuticals (NASDAQ:SYRS) and Argenx Se (NASDAQ:ARGX) with bullish sentiments. Syros Pharmaceuticals (SYRS) Oppenheimer analyst Leah R. Cann maintained a Buy rating

Syros Pharmaceuticals (SYRS) Receives a Hold from H.C. Wainwright

H.C. Wainwright analyst Andrew Fein maintained a Hold rating on Syros Pharmaceuticals (NASDAQ: SYRS) today and set a price target of $10. The company’s shares closed yesterday at $11.57. Fein noted: “Our price target of $10/share ($3.38 from tamibarotene +

Analysts Offer Insights on Healthcare Companies: Syros Pharmaceuticals (NASDAQ: SYRS), Melinta Therapeutics Inc (NASDAQ: MLNT) and Vericel Corp (NASDAQ: VCEL)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Syros Pharmaceuticals (NASDAQ:SYRS), Melinta Therapeutics Inc (NASDAQ:MLNT) and Vericel Corp (NASDAQ:VCEL) with bullish sentiments. Syros Pharmaceuticals (SYRS) Oppenheimer analyst Leah R. Cann

Cowen & Co. Assigns a Buy Rating on Syros Pharmaceuticals

In a report released today, Phil Nadeau from Cowen & Co. assigned a Buy rating to Syros Pharmaceuticals (NASDAQ: SYRS). The company’s shares opened today at $12.68. According to TipRanks.com, Nadeau is a 5-star analyst with an average return of

Syros Pharmaceuticals Receives a Hold from H.C. Wainwright

H.C. Wainwright analyst Andrew Fein maintained a Hold rating on Syros Pharmaceuticals (NASDAQ: SYRS) today and set a price target of $10. The company’s shares closed yesterday at $12.77. Fein said: “We point out that in preclinical studies, responses were

Oppenheimer Maintains Their Buy Rating on Syros Pharmaceuticals

Oppenheimer analyst Leah R. Cann maintained a Buy rating on Syros Pharmaceuticals (NASDAQ: SYRS) today and set a price target of $28. The company’s shares opened today at $12.12. Cann said: “For 2018 we have adjusted revenue to account for